Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Novel Compounds from Sycamore Leaves for the Treatment of MRSA

Award Number: R43AT008202
ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2015
PERIOD OF PERFORMANCE END DATE: 09/15/2016

Group Awards By:

View Award Description

Novel Compounds from Sycamore Leaves for the Treatment of MRSA - ¿ DESCRIPTION (provided by applicant): Methicillin-resistant staphylococcus aureus (MRSA) is a serious pathogen that can cause patient mortality and extend hospital stays, resulting in higher health care costs. Currently, over 50% of staph cases around the world are caused by MRSA. In recent years, MRSA has evolved into several resistant strains that can resist to multiple antibiotics such as penicillin, vancomycin, tetracycline and erythromycin. For this reason, they are sometimes called "superbugs." In recent years, these "superbugs" have become a serious threat to public health. Because of the increasing presence of MRSA-related infections, especially in hospitals, there are urgent needs for effective and novel antibiotic therapies. In a preliminary study, we have isolated a novel compound, kaempferol 3-O-alpha-L-(2",3"-di-p-coumaroyl)rhamnoside (KCR) from the American sycamore (Platanus occidentalis) that were active against MRSA and VRSA (vancomycin resistant staphylococcus aureus) in vitro and in vivo. The sycamore materials have been classified by the USDA as generally regarded as safe (GRAS) because of extensive human contact and use of this plant in traditional folk medicines and paper industry, among others. Active metabolites of these anti-MRSA compounds likely possess a distinct mechanism of action as they do not show cross resistance or structural homology with established antibiotics. In this proposal, we plan to furthe investigate these highly selective anti-MRSA KCR (platanosides) including the maximum tolerated dose (MTD), therapeutic efficacy, pharmacokinetics (PK), mechanism of action, and in vivo toxicity using animal model and microbiological techniques. This project clearly has the potential to generate a first in class new antibiotic with a novel mechanism of action and provides a unique opportunity for US economic development. In addition, the success of this project will address the limitations of current therapies for the control of MRSA and other antibiotic-resistant staph infections such as VRSA.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2015	21ST CENTURY THERAPEUTICS, INC.	440 BURROUGHS ST STE 100	DETROIT	MI	48202	WAYNE	USA	Research and Training in Complementary and Integrative Health	000	1	1/9/2017	NEW	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $4,784 )
2016	2016	21ST CENTURY THERAPEUTICS INC	52623 SEVEN OAKS	SHELBY TOWNSHIP	MI	48316	MACOMB	USA	Research and Training in Complementary and Integrative Health	000	1	11/23/2015	SUPPLEMENT FOR EXPANSION	$4,784
														Subtotal = $4,784

Issue Date FY: 2015 ( Subtotal = $303,745 )
2015	2015	21ST CENTURY THERAPEUTICS INC	52623 SEVEN OAKS	SHELBY TOWNSHIP	MI	48316	MACOMB	USA	Research and Training in Complementary and Integrative Health	000	1	8/10/2015	NEW	$303,745
														Subtotal = $303,745

Grand Total All Awards = $308,529

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel Compounds from Sycamore Leaves for the Treatment of MRSA

Award Number: R43AT008202

ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2015

PERIOD OF PERFORMANCE END DATE: 09/15/2016

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer